Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-04-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于昆药集团医药商业有限公司为云南省丽江医药有限公司提供1000万元银行综合授信额度担保的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding a guarantee provided by its subsidiary for a bank credit facility to another company. It details the guarantee amount, the parties involved, financial data of the guaranteed company, and the board's opinion on the guarantee. There is no indication of this being a financial report, audit, earnings release, or any other detailed report type. The document is an announcement of a specific corporate action related to financing support but does not report on capital raising or financing activities directly. It is not a regulatory filing of a financial report or management change. The content fits best under a general regulatory announcement category as it informs shareholders and the public about a material guarantee event. Given the document length (1582 characters) and content, it is not a report publication announcement or a detailed financial report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-04-15 Chinese
2018年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2018 年年度股东大会会议资料" which translates to "2018 Annual General Meeting (AGM) Materials" for KPC Pharmaceuticals, Inc. It contains detailed agenda items, voting procedures, reports from the board and independent directors, and other materials prepared for the 2018 Annual General Meeting held in April 2019. The content includes meeting notices, agenda, voting methods, and detailed reports to be discussed and voted on during the AGM. There is no indication that this is the actual annual report (10-K) or a summary earnings release, but rather the materials prepared for the AGM itself. The document length is substantial (15,000 characters), and it is not a brief announcement or a certification. Therefore, it fits the category of AGM Information (AGM-R).
2019-04-10 Chinese
关于《昆药集团股份有限公司关于股票交易异常波动有关事项的问询函》的回函
Regulatory Filings
2019-04-09 Chinese
关于公司股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company Kunming Pharmaceutical Group Co., Ltd. It discusses the reasons for the stock price volatility, risk factors related to a new industrial hemp processing project, and confirms that no undisclosed material information exists. The document is a formal disclosure to the stock exchange and investors about stock trading anomalies and related risks, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is a regulatory announcement about stock trading and company disclosures, fitting the category of Regulatory Filings (RNS). The document length is under 5,000 characters and is a standalone announcement, not a report publication announcement or other report type.
2019-04-09 Chinese
关于同意美国CPI股份有限公司合并的补充公告
Regulatory Filings Classification · 95% confidence The document is a supplementary announcement related to a previously disclosed merger involving the company and a US entity (CPI). It discusses shareholder information, confidentiality under Delaware law, and details about financing rounds and stock classifications. The document is relatively short (1004 characters) and serves as an update or supplement to an earlier announcement rather than a full report. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2019-04-04 Chinese
独立董事关于提名钟祥刚先生为公司董事候选人的独立意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their opinion on the nomination of a candidate for the company's board of directors. It references the nomination process and the qualifications of the candidate, which is typical of announcements related to board or management changes. The document is short and does not contain financial data or detailed report content, so it is not an annual report or financial report. It fits the category of Board/Management Information (MANG) as it concerns board candidate nomination and related independent opinions.
2019-04-03 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.